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ABSTRACT
Objective: To systematically review temporal changes in perioperative safety of carotid endarter-
ectomy (CEA) in asymptomatic individuals in trial and registry studies.
Methods: The MEDLINE and EMBASE databases were searched using the terms “carotid” and
“endarterectomy” and “asymptomatic” from 1947 to August 23, 2014. Articles dealing with
50%–99% stenosis in asymptomatic individuals were included and low-volume studies were
excluded. The primary endpoint was 30-day stroke or death and the secondary endpoint was
30-day all-cause mortality. Statistical analysis was performed using random-effects meta-
regression for registry data and for trial data graphical interpretation alone was used.
Results: Six trials (n5 4,431 procedures) and 47 community registries (n5 204,622 procedures)
reported data between 1983 and 2013. Registry data showed a significant decrease in postop-
erative stroke or death incidence over the period 1991–2010, equivalent to a 6% average pro-
portional annual reduction (95% credible interval [CrI] 4%–7%; p , 0.001). Considering
postoperative all-cause mortality, registry data showed a significant 5% average proportional
annual reduction (95% CrI 3%–9%; p , 0.001). Trial data showed a similar visual trend.
Conclusions: CEA is safer than ever before and high-volume registry results closely mirror the
results of trials. New benchmarks for CEA are a stroke or death risk of 1.2% and a mortality risk
of 0.4%. This information will prove useful for quality improvement programs, for health care fun-
ders, and for those re-examining the long-term benefits of asymptomatic revascularization in
future trials. Neurology® 2015;85:1–8
GLOSSARY
ACAS5Asymptomatic Carotid Atherosclerosis Study;ACST-15Asymptomatic Carotid Surgery Trial 1;CaRESS5Carotid
Revascularization Using Endarterectomy or Stenting Systems; CEA 5 carotid endarterectomy; CREST 5 Carotid Revascu-
larization Endarterectomy versus Stenting Trial; CrI 5 credible interval; GALA 5 General Anaesthesia Versus Local Anaes-
thesia for Carotid Surgery; OR 5 odds ratio; PrI 5 prediction interval.
Carotid endarterectomy (CEA) in asymptomatic individuals was introduced in the 1970s for
long-term prevention of ipsilateral stroke1 and now comprises the bulk of those undergoing
endarterectomy in the United States.2 However, the 10-year absolute risk reduction in stroke or
death risk in the largest and most recent trial, the Asymptomatic Carotid Surgery Trial
1 (ACST-1), was only 4.6%, demonstrating small absolute benefit of CEA.3,4
On modern medical therapy, ipsilateral ischemic stroke rates have fallen,5 with 3 recent
cohort studies demonstrating annual ipsilateral ischemic stroke risks in patients with 50%–
99% asymptomatic stenosis of 0.3%–0.8%,6–8 less than the 0.96% risk in ACST.4 If CEA is to
prove effective in the future, one of the prerequisites is that perioperative outcomes must become
safer not only in trials, but in wider clinical practice.
The aim of this systematic review was to examine temporal trends in perioperative safety of
CEA in asymptomatic individuals with 50%–99% internal carotid artery stenosis. When com-
pared with symptomatic patients,9 the benefits of asymptomatic revascularization are less
pronounced, and without marked improvements in operative safety, asymptomatic revascular-
ization faces becoming a historical footnote. This analysis will provide valuable information for
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patients, clinicians, and those designing trials,
and establish a benchmark for those funding
reimbursement for safe surgery.
METHODS Search strategy and selection criteria. Two
independent reviewers (A.B.M., M.I.Q.) performed a systematic
literature review on August 23, 2014, according to Preferred Re-
porting Instructions for Systematic Reviews and Meta-Analyses
guidelines.10 The MEDLINE and EMBASE databases were
searched using key words “carotid” and “endarterectomy” and
“asymptomatic” to identify all published studies from 1947 to
August 23, 2014. No filters or limits were applied. Disagreements
were settled by an independent, experienced reviewer (A.T.). The
search process is summarized in figure 1.
Articles published in any language were included if they sat-
isfied the following criteria: registered research trials or surgical
registries; analyzable data for a subset of patients with 50%–
99% carotid stenosis and no recent ipsilateral or contralateral
symptoms; and extractable incidence of 30-day perioperative
stroke or death. Articles were excluded if they satisfied any one
of the following 6 criteria: (1) studies exclusively concerning
carotid angioplasty and stenting; (2) patients undergoing surgery
for recurrent or nonatherosclerotic carotid disease; (3) patients
undergoing staged contralateral carotid or combined cardiac pro-
cedures; (4) review articles, editorials, letters, case reports, case
series, animal studies, and studies investigating the morphology or
histology of atheromatous carotid plaques; (5) studies reporting
data for fewer than 100 asymptomatic procedures, as the expected
differences in perioperative risk were of the order of 1%, and thus
cannot be precisely determined from small studies11; or (6) studies
spanning more than a decade. One study12 reporting registry data
from July 1976 to November 1993 was excluded as operations
over this 17-year period were summated, the opposite of the
purpose of this review.
Data extraction. Articles were title, abstract, and full text
screened. In the absence of sufficient data, authors were contacted
by e-mail for further information. Two databases were compiled
for analysis: research trials and clinical registries (tables e-1 and
e-2 on the Neurology® Web site at Neurology.org, respectively).
Data were extracted for one artery per patient where possible, to
avoid clustering. Quality assessment of research trials followed
CONSORT principles13 (table e-3), which were adapted for
clinical registries (table e-4). Perioperative stroke or death,
measured as 30-day incidence, was chosen as the primary
composite endpoint as it reflects the outcomes the procedure is
designed to prevent. It is the conventional safety endpoint for
CEA in international guidelines.14,15 The secondary endpoint was
all-cause mortality (death), an endpoint less sensitive to reporting
bias, as it does not require a neurologist.9 Information on
myocardial infarction was available but its definition has
changed over time16 and only 3 trials reported data. Endpoints
were adjudicated locally and not centrally by the authors of this
study. The extraction of event frequencies was performed as
follows: the denominator was the actual number of CEAs
performed, not the number randomized (i.e., a per-protocol
analysis). The numerator was the number of events that
followed surgery to 30 days.
Statistical analysis. An independent statistician (A.J.F.) per-
formed the statistical analysis. For each study, the number of
30-day perioperative events and the total number of procedures
was reported during the trial period. Given this format of the
data, the mean 30-day incidence of perioperative events was
assigned to the midpoint of the study recruitment period.
Trials and registries were considered separately. Analysis of the
former was limited to visual inspection of a scatterplot because
of the low number of studies (figures 2 and 3). In the case of
clinical registry data, a logistic meta-regression random-effects
model for the intercept was conducted with 30-day incidence
as the outcome and time as the explanatory covariate (figures 4
and 5). A random-effects meta-regression was adopted, aimed at
estimating the effect of time on the average perioperative outcome
with the rest of the variability between studies assumed to be
overall random. A Bayesian approach was adopted by
conducting the analysis in JAGS version 3.4.0 as detailed in the
data supplement.17
RESULTS Excluded studies. No data from the ongo-
ing Stent-Protected Angioplasty in Asymptomatic
Carotid Artery Stenosis vs Endarterectomy
(SPACE2),18 Asymptomatic Carotid Surgery Trial 2
(ACST-2),19 and European Carotid Surgery Trial 2
(ECST-2) trials were available on request. Data from
Stenting and Angioplasty with Protection in Patients
at High Risk for Endarterectomy (SAPPHIRE) were
excluded because this was a trial specifically for high
risk for endarterectomy patients.20 Data from 4
randomized controlled trials were not included
because fewer than 100 CEAs in asymptomatic
patients were performed during each study21–24
Figure 1 Preferred Reporting Instructions for Systematic Reviews and Meta-
Analyses diagram illustrates search results
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(range 7–84), leaving 6 research trials.3,4,25–28 Forty-
seven registries were reported in 17 separate
publications.29–45
Included study characteristics. There were 6 eligible
research trials comprising 4,431 endarterectomies,
with recruitment between 1983 and 2008. There
were 47 eligible clinical registries comprising
204,622 endarterectomies performed between 1991
and 2013. The event rates and characteristics of
the trial and registry papers are detailed in tables e-1
and e-2, respectively.
Four out of 6 research studies were conducted in
North America and 2 in Europe. Five were random-
ized controlled trials and the sixth was a high-quality
cohort study.27 The number of endarterectomies
ranged from 170 to 1,405 per study. Operator expe-
rience ranged from a minimum of 2 years’ experi-
ence25 to 50 CEAs per year with a ,3% stroke or
death rate.27 The demographics of patients in all the
trials were similar with an average age of 64–72 years
and 65%–70% of participants were male. Medical
treatment consisted of aspirin alone in Veterans Af-
fairs; aspirin and discussion of risk factors in Asymp-
tomatic Carotid Atherosclerosis Study (ACAS);
aspirin, statins, and antihypertensives to varying de-
grees in ACST and Carotid Revascularization Endar-
terectomy versus Stenting Trial (CREST); and was
not stated in General Anaesthesia Versus Local Anaes-
thesia for Carotid Surgery (GALA) and Carotid
Revascularization Using Endarterectomy or Stenting
Systems (CaRESS). Inclusion criteria ranged from
50% to 99% stenosis in Veterans Affairs to 75%–
99% stenosis in CaRESS and were not stated in
GALA. Asymptomatic status was defined as “absence
of cerebral infarction” in Veterans Affairs, “absence of
cerebrovascular events or symptoms referable to the
contralateral cerebral hemisphere within the previous
45 days” in ACAS, and “without stroke, transient
cerebral ischemia or other relevant neurologic symp-
toms in the past 6 months” in ACST-1 and CREST
and was not further specified in GALA or CaRESS.
Endpoint adjudication was by an independent neu-
rologist in all cases and 4 out of 6 studies had a
blinded endpoint committee. Four studies were
funded through government or charitable grants,
with one industry-sponsored study and one with a
mixture of both.
Of the 47 clinical registries, 17 were based in the
United States, 11 in Germany, 4 each in Canada and
the United Kingdom, 3 in Sweden, 2 in Australia,
and a single dataset each from Austria, Finland, Hun-
gary, Italy, Norway, and Switzerland. They com-
prised a mixture of vascular society, reimbursement
claims, Veterans Affairs registries, and regional audits.
The number of endarterectomies ranged from 113 to
17,692 per registry. There were no data on operator
experience, patient demographics, medical treatment,
or funding. Only one study had a small (7%) propor-
tion of patients reviewed by an independent neurolo-
gist postprocedure.34 Inclusion criteria ranged from
“no documented history of ipsilateral cerebral ische-
mia”33 to “no ipsilateral hemispheric symptoms in the
past 6 months”38 and in 6 cases were not stated.
Exclusion criteria were variable. In Medicare claims
registries, it was assumed the data were from consec-
utive patients for reimbursement purposes; however,
this was not necessarily the case for other registries.
Temporal trends in clinical trials. The scatterplot in
figure 2 illustrates that 30-day incidence of stroke
or death shows a trend toward reduction over the
last 30 years, from 4.3% reported in Veterans
Affairs to ,1.8% in CaRESS and CREST.
However, this is reliant on the validity of the results
from Veterans Affairs and ACAS. Without further
Figure 2 Temporal trends in 30-day perioperative stroke or death incidence in
clinical trials
Horizontal bar corresponds to recruitment period and size of bubble proportional to preci-
sion (reciprocal of variance) of results. ACAS 5 Asymptomatic Carotid Atherosclerosis
Study; ACST 5 Asymptomatic Carotid Surgery Trial; CaRESS 5 Carotid Revascularization
Using Endarterectomy or Stenting Systems; CREST 5 Carotid Revascularization Endarter-
ectomy versus Stenting Trial; GALA 5 General Anaesthesia Versus Local Anaesthesia for
Carotid Surgery.
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data points, the significance of this trend is uncertain.
Furthermore, in early trials such as Veterans Affairs
and ACAS, 0.4%–1.2% of patients had stroke or
death as a result of routine diagnostic arteriography,
before the introduction of duplex. These
arteriographic complications are not included in the
30-day outcomes but are recorded in the data
supplement.
For perioperative death alone (figure 3), a similar
visual trend was apparent, with a reduction from
1.9% in Veterans Affairs to ,0.2% in CaRESS and
CREST. This was also dependent on the results from
Veterans Affairs and ACAS. Without further data
points, the significance of this trend is also uncertain.
Again in Veterans Affairs and ACAS, an additional
0%–0.2% of patients had a preprocedural death
related to diagnostic arteriography.
Temporal trends in clinical registries. There was a statisti-
cally significant decrease in 30-day perioperative stroke
or death incidence over the period 1991–2013, odds
ratio (OR) 0.94 (95% credible interval [CrI] 0.93–
0.96, p , 0.001), translating into a 6% mean annual
decrease in risk, relative to the previous year. There was
high heterogeneity (I2 5 78, 95% CrI 70%–85%), as
might be expected from registry data. The expected
incidence of stroke or death for 1992 was 3.9%
(95% CrI 3.0%–4.9%), with a 95% prediction
interval (PrI) of 1.9%–7.7%. The respective figure
for the last reported timepoint of 2013 was 1.2%
(95% CrI 1.0%–1.5%), with a 95% PrI of 0.6%–
2.4%. These data do not include preprocedural
arteriography-related events.
Similarly, there was a statistically significant
decrease in the 30-day incidence of mortality over
the period 1991–2013, OR 0.95 (95% CrI 0.92–
0.97, p , 0.001), translating into a 5% mean annual
risk reduction. There was high heterogeneity despite
the use of the hard endpoint of death, I2 5 57%
(95% CrI 18%–77%). The mean incidence of death
in 1992 was 1.3% (95% CrI 0.9%–1.8%), with a
95% PrI of 0.6%–2.5%. The respective figure for
the last reported time point of 2013 was 0.4%
(95% CrI 0.3%–0.5%), with a 95% PrI of 0.2%–
0.8%. These data do not include preprocedural
arteriography-related events.
Heterogeneity across studies. The distribution of the
posterior median contribution to the Cochran Q of
each individual study revealed that heterogeneity
was due to 5 studies: 4 for death or stroke32,37,40,43
(Vikatmaa et al.40: Italy data from VASCUNET
[2007–2009]) and 136 for death only incidence. Sen-
sitivity analysis was performed by excluding data from
these studies. In this scenario, heterogeneity was
substantially reduced, as expected; however, the OR
estimates showed no significant difference from the
base case analysis.
DISCUSSION The results of this analysis demonstrate
that the average 30-day incidence of stroke or death has
decreased by almost two-thirds both in large-volume
international registries and clinical trials over the last
30 years, from approximately 4% to less than 1.5%
by 2013. A significant temporal improvement in
operative safety was seen in registry data, but was less
certain in trial data, due to limited data. As the 95%
prediction intervals overlap in 1992 and 2013 for
registry studies, it is clear that the results of some of
the best performing centers in 1992 are equivalent to
the worst performing centers in 2013. However, on
average, there has been a significant temporal
improvement in operative safety. It should be borne
in mind that there was an additional risk of around
1% of a preprocedural stroke or death in early
studies due to the need for routine diagnostic
catheter arteriography. The temporal trends for death
Figure 3 Temporal trends in 30-day perioperative death incidence in clinical
trials
Horizontal bar corresponds to recruitment period and size of bubble proportional to preci-
sion of results. ACAS 5 Asymptomatic Carotid Atherosclerosis Study; ACST 5 Asymptom-
atic Carotid Surgery Trial; CaRESS 5 Carotid Revascularization Using Endarterectomy or
Stenting Systems; CREST 5 Carotid Revascularization Endarterectomy versus Stenting
Trial; GALA 5 General Anaesthesia Versus Local Anaesthesia for Carotid Surgery.
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alone were nearly identical with a reduction in
incidence from.1% to,0.5% over the last 30 years.
There was high heterogeneity in the registry re-
sults for stroke or death and also for the more robust
endpoint of death alone. These may reflect selection
bias, operator experience, adjudication, and reporting
bias in these lower quality studies. In the future,
explicit descriptions of asymptomatic status, method
of calculation of stenosis, baseline medical therapy,
endpoint adjudication, procedural technique, and
adjunctive medications used perioperatively should
be provided to explore heterogeneity in more detail.
Notably, some better performing centers have re-
ported outcomes pre-2000 that were equivalent to
worse performing centers in 2013.
No temporal analysis has previously been per-
formed in asymptomatic patients. This study ana-
lyzed research trial and registry data separately for
average risk asymptomatic patients for CEA over
the last 30 years. This approach allowed comparison
of results from selected patients in expert centers with
results from wider clinical practice, to provide infor-
mation of what can be achieved alongside what is
actually being achieved. Similar temporal trends were
found for the endpoints of stroke or death and for the
more robust endpoint of death alone as well as when
excluding the main sources of heterogeneity in the
registry data.
It is important to discuss the limitations of this
study. First, source data for individual studies were
presented over a range of years and breakdown by
year was not possible due to the age of some of the
studies. This was accounted for by assigning the mean
30-day incidence to the midpoint of the study period
and excluding studies that spanned a decade or more.
Second, a minority of patients had more than one
procedure, which may have introduced a small degree
of clustering. Third, it is well-established that a
volume-outcome relationship exists with carotid sur-
gery46 and it is probable that poor performers were
less likely to submit data and therefore registry results
may represent high volume, safer centers. Risks out-
side of these institutions cannot be extrapolated from
this study. Fourth, it is acknowledged that registry
data are less robust than trial data. It was important
to incorporate registry data in this analysis for several
reasons: registries capture real-world practice, have
greater power to detect temporal trends in rare out-
comes due to larger numbers, report the results of
modern-day procedures performed up to 5 years after
randomized trials close, and report results outside of
the United Kingdom and United States. This prob-
lem was addressed by comparing the results of regis-
tries with the results of trials to look for consistency,
as well as considering the endpoint of death alone,
which did not rely on the adjudication of an indepen-
dent neurologist. Fifth, results for stenosis subgroups
were not examined, as subgroup data were not
extractable. However, it has been demonstrated that
stenosis is a weak predictor of future stroke47 and did
not predict benefit from endarterectomy in ACAS3 or
ACST.4 It is therefore largely irrelevant in considering
operative safety. Sixth, due to the small number of
research trials, no quantitative analysis could be per-
formed, as the results would be sensitive to outliers.
Finally, it could be suggested that the results from the
Veterans Affairs trial are an outlier. Nevertheless, US
case series from the same decade show a perioperative
stroke incidence of 7.7%48 and 4.2%,49 respectively,
with mortality quoted in the former of 3.1%. These
corroborate the results of Veterans Affairs during this
time period.
In an earlier study of symptomatic patients under-
going endarterectomy, no significant change in peri-
operative risks was found between 1985 and 2008.9
Figure 4 Temporal trends in 30-day perioperative stroke or death incidence in
clinical registries
Meta-regression using random effects model with bubble size proportional to study preci-
sion. There was a statistically significant decrease in 30-day perioperative stroke or death
incidence over the period 1991–2013, odds ratio 0.94 (95% credible interval 0.93–0.96,
p , 0.001), translating into a 6% year on year mean risk reduction. The limits of the 95%
credible interval and prediction interval have been drawn respectively in red and in blue.
These data do not include preprocedural arteriography-related events.
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During this period, symptomatic patients were being
operated on sooner after the index event, at more
advanced ages with an anticipated increase in periop-
erative risks.50 Elective asymptomatic carotid surgery
is different as time is available for prior optimization
of medical therapy and for stringent patient and oper-
ator selection, which should improve outcomes.
The results of this study can be interpreted as fol-
lows: over the last 30 years, there has been on average
a decrease by almost two-thirds in perioperative
stroke or death and death risk during CEA. The
reasons for this are multifactorial, but we suggest
the following: more technical experience, increasing
preoperative use of statin51 and dual antiplatelet
therapy,52 postoperative blood pressure control,53
improved patient selection, centralization of carotid
surgery,46 and patch closure.54 For example, in the
early Veterans Affairs trial, medical therapy consisted
of aspirin alone, whereas by the end of ACST-1 in
2007, more than 80% of patients were receiving
antihypertensive and statin therapy.4 Similarly, before
the early results of ACST-1, surgeons were routinely
operating on asymptomatic patients older than 75
years, whereas European guidelines changed after
this trial, recommending an age limit of ,75 years
in men and lower in women.55 The publication of
better high-volume center outcomes in the United
Kingdom has led to its Vascular Society recommend-
ing fewer, higher-volume vascular units.56 Finally, the
introduction of patch arterial closure was demon-
strated by Cochrane reviews to lower the periopera-
tive risk of stroke or death.54 To address the variability
in these factors, national audit of consecutive cases is
recommended to allow centers to compare outcomes.
In the United Kingdom, this has now been extended
to individual surgeon outcomes. The results of this
study provide a benchmark against which to compare
outcomes internationally for surgeons, trialists, and
health care funders.
It is argued by some that CEA for asymptomatic
atherosclerosis has no place in modern medicine.
However, despite improvements in primary preven-
tion, the EUROASPIRE studies demonstrated that
a large proportion of the European population are still
failing to achieve control of cardiovascular risk factors,
notably smoking, hypertension, diabetes, and obe-
sity.57 Among those who fail to attain best medical
therapy targets, there may be candidates for preven-
tative carotid surgery, in whom the background
stroke risk may be much higher.
The implications of this study for clinicians and
patients are that the risks quoted from the early land-
mark ACST-1 and ACAS trials are out of date. New
benchmarks for high-quality endarterectomy are a
30-day stroke or death rate of 1.2% and a 30-day
mortality of 0.4%. The results of trials are today
closely replicated in centers submitting registry data.
Whether long-term efficacy for endarterectomy over
medical therapy still exists for a specific population re-
quires reexamination based on this evidence.
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